Cantor Fitzgerald Estimates CATX FY2026 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Perspective Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($0.99) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share.

Several other equities research analysts have also recently commented on the company. Scotiabank assumed coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Truist Financial reduced their price target on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday, March 31st. Finally, Royal Bank of Canada upgraded Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their price objective for the stock from $15.00 to $16.00 in a research report on Tuesday, June 3rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $12.63.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded up $0.20 on Tuesday, reaching $3.43. The company's stock had a trading volume of 2,105,743 shares, compared to its average volume of 1,084,615. The stock's 50-day moving average is $2.36 and its two-hundred day moving average is $2.87. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $16.55.

Insider Buying and Selling at Perspective Therapeutics

In related news, Director Robert F. Williamson III bought 22,192 shares of the firm's stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.27 per share, with a total value of $50,375.84. Following the completion of the transaction, the director now directly owns 70,837 shares of the company's stock, valued at approximately $160,799.99. This represents a 45.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Juan Graham acquired 33,333 shares of the stock in a transaction on Friday, March 28th. The stock was purchased at an average cost of $2.25 per share, with a total value of $74,999.25. Following the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. This represents a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 115,696 shares of company stock valued at $256,344 over the last ninety days. Corporate insiders own 3.72% of the company's stock.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $4,132,000. Two Sigma Advisers LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $484,000. JPMorgan Chase & Co. raised its stake in shares of Perspective Therapeutics by 498.3% in the 4th quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock valued at $475,000 after purchasing an additional 124,133 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of Perspective Therapeutics in the 4th quarter valued at about $51,000. Finally, Two Sigma Investments LP bought a new position in shares of Perspective Therapeutics during the fourth quarter worth about $2,075,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.